Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N0783 vs Alenia in Moderate Asthma
NCT07318350Phase 3Withdrawn
- Sponsor
- Eurofarma
- Start
- Oct 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of N0783 in asthma (2 arms), sponsored by Eurofarma. Primary endpoint: Absolute change in pre-bronchodilator FEV1 at 12 weeks. Planned start Oct 2026; status: withdrawn.
02
Drugs
N0783
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07318350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318350.